Loading the latest PSX data…
Loading the latest PSX data…
Ferozsons Laboratories LimitedShariah-compliant
−3.50 (−0.96%) today
Market closed, last update Nov 17, 2026 11:07 PMThe Ferozsons Laboratories share price was Rs 361.42 (−0.96%) at the last PSX update (Nov 17, 2026 11:07 PM). FEROZ is a pharmaceuticals stock with a market value of Rs 15.7bn.
Last session's range17 Nov 2026
358.0034% up the range368.20
52-week range
293.0138% up the range475.00
Price limits (circuit breakers)
328.4345% up the range401.41
FEROZ ranks better than 39% of the 311 liquid PSX stocks we score. Each factor is a 0-100 rank (value is ranked half within pharmaceuticals). Education only, not a buy or sell signal.
−7.3% over 6M(KSE-100 +5.5%)
Daily bars from PSX's end-of-day market summary. Prices before a bonus issue, right issue or split are adjusted so the chart stays continuous; cash dividends are not taken out.
Full-screen FEROZ chart with levelsDownload FEROZ price history (CSV)Compare FEROZ with GLAXO
From daily closes to 2026-11-17. A description of the trend, not a forecast.
Trend reading
Mixed
Down3 up · 2 down signalsUp
| S2 | S1 | Pivot | R1 | R2 |
|---|---|---|---|---|
| 352.34 | 356.88 | 362.54 | 367.08 | 372.74 |
+12.6% over 5 years
Monthly closing prices from the PSX Data Portal, since 2000. Earlier prices are adjusted for 8 bonus issues and splits (2004–2022; one share then is about 6.1 shares now) so the line shows the value of one original share.
| Announced | Period | Payout | Profit after tax | EPS (Rs) | Books close |
|---|---|---|---|---|---|
| 29 Oct 11:14 | 1st quarter to 30 Sept | None | – | 7.40 | – |
| 29 Oct 11:13 | 1st quarter to 30 Sept | None | Rs 219.6m | 5.05 | – |
| 29 Sept 15:38 | Full year to 30 Jun | None | – | 22.51 | – |
| 29 Sept 15:37 | Full year to 30 Jun | Final cash dividend 55% | Rs 650.9m | 14.97 | 21 Oct – 28 Oct |
| 11 Jun 15:45 | – to – | None | – | – | 27 Jun – 3 Jul |
| 29 Apr 15:37 | 9 months to 31 Mar | None | – | 16.92 | – |
| 29 Apr 15:37 | 9 months to 31 Mar | None | Rs 503.9m | 11.59 | – |
| Measure | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Sales growth | +13.7% | +9.0% | +28.5% | – |
| Profit growth | +23.2% | +32.0% | +111.6% | – |
| EPS growth | +23.2% | +32.1% | +111.5% | – |
| Net margin | 4.1% | 3.8% | 3.1% | 1.9% |
| Measure | Q1 2027 | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Sales growth | +22.9% | – | – | – |
| Profit growth | +20.4% | – | – | – |
| EPS growth | +20.2% | – | – | – |
| Net margin | 4.6% | 4.1% | 3.9% | 4.7% |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Sales | Rs 15.8bn | Rs 13.9bn | Rs 12.7bn | Rs 9.9bn |
| Profit after tax | Rs 651m | Rs 528m | Rs 400m | Rs 189m |
| Earnings per share (Rs) | 14.97 | 12.15 | 9.20 | 4.35 |
| Line item | Q1 2027 | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Sales | Rs 4.8bn | Rs 3.7bn | Rs 4.4bn | Rs 3.9bn |
| Profit after tax | Rs 220m | Rs 150m | Rs 171m | Rs 182m |
| Earnings per share (Rs) | 5.05 | 3.46 | 3.93 | 4.20 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Gross margin | 42.1% | 41.3% | 38.9% | 38.6% |
| Net margin | 4.1% | 3.8% | 3.2% | 1.9% |
| EPS growth | 23.2% | 32.1% | 111.5% | -63.2% |
| PEG | 1.16 | 1.00 | 0.24 | -0.50 |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report. Latest quarter (Q1 2027) EPS rose 20.2% from the same quarter a year earlier.
| Measure | FEROZ | Sector median | Reading |
|---|---|---|---|
| P/E | 22.8 | 12.1 | Dearer than peers |
| Dividend yield | 1.6% | 5.2% | Below peers |
| Net margin | 4.1% | 9.4% | Below peers |
| EPS growth | +23.2% | +34.5% | Below peers |
| 1-year return | −9.0% | −14.9% | Above peers |
Sector P/E check. At the sector's median P/E of 12.1, last year's EPS of Rs 14.97 would price FEROZ at about Rs 181.28 (−50% from today). A rough yardstick only: sectors hold very different businesses, and the market prices future profits, not last year's.
Estimate a fair value for FEROZ (Graham, Lynch, DCF)FEROZ pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your FEROZ dividend income after tax
| Announced | Period to | Payout | Cash per share | Books closed |
|---|---|---|---|---|
| 29 Sept 2026 | 30 Jun 2026 | Final cash dividend 55% | Rs 5.50 | 21 Oct 2026 – 28 Oct 2026 |
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
8th of 18
Rs 15.7bn
P/E (cheapest first)
12th of 13
22.8
Dividend yield
7th of 7
1.6%
1-year return
6th of 15
-9.0%
EPS growth
10th of 15
23.2%
Net margin
14th of 16
4.1%
danioPSX score
10th of 13
39/100
| GLAXOGlaxoSmithKline Pakistan Limited | Rs 106.1bn | −1.89% | 9.7 | 6.1% | −15.4% | 87 |
| ABOTAbbott Laboratories (Pakistan) Limited | Rs 98.5bn | +0.18% | 10.6 | 4.4% | −7.6% | 81 |
| HALEONHaleon Pakistan Limited | Rs 79.8bn | −1.15% | 12.2 | 3.6% | −16.6% | 67 |
| HINOONHighnoon Laboratories Limited | Rs 51.1bn | +0.89% | 12.4 | 5.4% | −14.3% | 78 |
| SEARLThe Searle Company Limited | Rs 46.6bn | −0.37% | 12.0 | – | −23.6% | 53 |
| AGPAGP Limited | Rs 43.2bn | −0.84% | 24.1 | 5.1% | −18.3% | 49 |
| HPLHoechst Pakistan Limited | Rs 38.8bn | +0.53% | 11.1 | 6.9% | −2.7% | – |
| FEROZThis stock · Ferozsons Laboratories Limited | Rs 15.7bn | −0.96% | 22.8 | 1.6% | −9.0% | 39 |
| CPHLCiti Pharma Ltd. | Rs 14.4bn | −0.74% | 17.7 | – | −23.2% | 31 |
| GSKCHGlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| BFBIOBF Biosciences Limited | Rs 12.0bn | −0.60% | 18.2 | – | −10.8% | 45 |
| MACTERMacter International Limited | Rs 11.7bn | −1.08% | 3.7 | – | −27.9% | 52 |
| SAPLSanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.7bn | +0.79% | 11.6 | – | +39.6% | 65 |
| LIVENLiven Pharma Limited | Rs 5.4bn | +10.00% | – | – | −2.3% | 15 |
Swipe the table sideways for more columns.
No director or substantial-shareholder trades in FEROZ read from PSX notices yet.
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
Ferozsons Laboratories Limited was incorporated as a private limited company on 28 January 1954 and was converted into a public limited company on 08 September 1960. The Company is primarily engaged in the imports, manufacture and sale of pharmaceutical products and medical devices.
Where the price sits in its 52-week range
Low 293.0138% of the way upHigh 475.00
Data: PSX Data Portal (Nov 17, 2026 11:07 PM); company data refreshed 17 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell FEROZ. Official PSX page for FEROZ